29 October 2024 in Aesthetic Surgery Journal
Predictors for permanent nipple-areola complex (NAC) insensitivity after reduction mammoplasty are sparsely defined. We analyze factors associated with NAC insensitivity over a long-term follow-up. A retrospective analysis of reduction mammoplasties on 1598 breasts performed by four surgeons from March 2015–February 2023 was conducted. Data on patient demographics, intraoperative factors, and postoperative complications were collected from patient records. Analysis was conducted by breast, separated into breasts with NAC insensitivity (permanent and transient) and those without. Wilcoxon rank sum test for continuous variables and Fisher’s exact test or Pearson’s Chi-square test for categorical variables evaluated differences between the groups. Univariate and multivariate logistic regression analyzed the association of pedicle choice with NAC insensitivity onset and permanence. Of 1598 breasts, 9.8% had loss of NAC sensation, of which 49.0% had permanent loss. 51.0% regained sensitivity, taking an average of 116 days (median 64, range 6–798) to regain sensation. NAC-insensitive breasts had a longer sternal notch–NAC (p<0.001) and NAC–IMF (p<0.001) measurements, greater weight removed (p<0.001), and fat necrosis co-complication (p=0.022). Greater weight removed (p=0.044) and longer sternal notch–NAC measurements (p=0.011) were associated with permanent insensitivity. The superomedial pedicle was associated with an increased rate of transient NAC insensitivity, while the inferior pedicle with a decreased rate. There was no significant association between pedicle choices and permanent insensitivity. Transient loss of NAC sensitivity is associated with pedicle choice, while breasts with permanent insensitivity were more likely to have longer breast measurements and a greater amount of tissue removed.
15 February 2024 in Burns
19 February 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
23 October 2023 in Dermatologic Surgery
17 February 2024 in World Neurosurgery
15 January 2026 in JPRAS Open
The growing use of tranexamic acid (TXA) in plastic surgery warrants an accurate analysis of efficacy for body contouring indications. We offer the largest cohort evaluation of intravenous TXA use in minimizing postoperative complications following reduction mammoplasty. A single-institution retrospective analysis was conducted on consecutive reduction mammoplasty procedures performed between February 2023–August 2024. Patient demographics, intraoperative factors, and postoperative complications were collected and summarized using descriptive statistics. Groups were stratified based on administration of TXA, with differences assessed using Pearson’s chi-square test for categorical variables and Student’s t-test or Wilcoxon rank sum test for continuous variables, as appropriate. Association of perioperative intravenous TXA use with postoperative complications was analyzed by breast with multivariable logistic regression. Of 406 patients (812 breasts), 213 patients (426 breasts) were administered TXA perioperatively. Neither group had significant differences in Caprini score, prior history of DVT, or anemia. Multivariable regression analysis, controlling for differences in demographics and operative characteristics, demonstrated that TXA use was significantly associated with decreased rates of dehiscence (aOR = 0.50, 95% CI 0.28–0.91, p = 0.023) and scar revision (aOR = 0.30, 95% CI 0.12–0.76, p = 0.015). Among breasts that were only closed with barbed sutures, after adjustment for demographics and operative characteristics, TXA use was significantly associated with lower rates of scar revision only (aOR = 0.16; 95% CI 0.05–0.52; p = 0.005). Intravenous TXA use in reduction mammoplasty confers lower rates of postoperative wound complications, though its impact may be secondary to wound closure technique.